Clinical trials
Medullary Thyroid Carcinoma clinical trials
Below are recruiting medullary thyroid carcinoma clinical trials, each written for real people, not researchers. We’re tracking 22 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+ - NCT07713901Enrolling by invitation
Study of medication risk for rare thyroid cancer
This study looks at medical records to see if certain medications might be linked to a rare thyroid cancer (medullary thyroid carcinoma). You don't need to do anything new—just your existing health data will be reviewed.
Parsippany, New JerseyAges 18 years+ - NCT03892993Recruiting
Decision aid for medullary thyroid cancer treatment choices
This study tests a patient-and-caregiver decision guide to help you decide when to start or stop a new cancer drug, join a clinical trial, or continue active surveillance. It aims to make tough choices feel clearer and more supported.
Houston, TexasAges 18 years+ - NCT04216732Recruiting
Study of medullary thyroid cancer progression in a registry
This study follows people with medullary thyroid cancer to better understand how the disease changes over time, including in advanced stages. You may help improve future treatment planning and care for people with medullary thyroid cancer.
San Francisco, CaliforniaAges 18 years+ - NCT05830500RecruitingPhase 4
Anlotinib for advanced medullary thyroid cancer
This trial studies anlotinib in people with advanced or metastatic medullary thyroid cancer that has been getting worse. It aims to see how well the treatment controls the cancer and how safe it is for patients who can’t have curative surgery.
Hefei, AnhuiAges 18–75 - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06520319RecruitingPhase 1
Comparing two PET tracers for recurrent MTC
This study compares a new imaging agent called 68Ga-MGS5 with the standard agent 68Ga-DOTATATE to see which one better detects recurrent medullary thyroid carcinoma on a PET/CT scan. The goal is to improve tumor detection in people whose MTC has returned.
Fuzhou, FujianAges 18–80 - NCT06863805Recruiting
Blood markers in advanced thyroid cancer
This study is looking at how certain substances in the blood (called biomarkers) can help doctors understand and treat advanced thyroid cancer. It is for people who are about to start their first systemic therapy (medication that works throughout the body) for advanced thyroid cancer, and who have already had a genetic test on their tumor.
BolognaAges 18 years+ - NCT01511393Enrolling by invitation
Tracking people with thyroid cancer to learn its course
This study follows adults who have medullary thyroid cancer (MTC) to learn how the cancer behaves over time. It may help by improving future care and follow-up strategies for people with MTC.
Morgantown, West VirginiaAges 18 years+ - NCT06852144Enrolling by invitation
PET-CT scan for thyroid and parathyroid evaluation
This study looks at how well PET-CT scans can find thyroid or parathyroid problems. The trial uses scans that are already part of your regular care to learn more about these conditions.
Bologna, BoAges 18 years+ - NCT07142005Recruiting
Educational tool for Hispanic medullary thyroid cancer patients
This study tests a culturally tailored educational tool to help Hispanic or Latino/a patients with medullary thyroid cancer and their caregivers make informed decisions. It aims to improve understanding and support for Spanish-speaking individuals.
Houston, TexasAges 18 years+ - NCT07545837Recruiting
Wellness Coaching for Thyroid Cancer Survivors
This study tests whether personalized health coaching helps thyroid cancer survivors stick to their treatment plans and build healthier habits. You'll work with a coach to improve your overall wellness after thyroid cancer treatment.
Jacksonville, FloridaAges 18 years+ - NCT07138716Recruiting
PET/CT scan for medullary thyroid carcinoma
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
Beijing, Beijing MunicipalityAges Any age - NCT07383246RecruitingPhase 3
FAPI-guided surgery for newly diagnosed medullary thyroid cancer
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
Beijing, Beijing MunicipalityAges Any age - NCT07357571Recruiting
Can ultrasound help predict lymph node spread in early thyroid cancer?
This trial uses contrast-enhanced ultrasound before surgery to see if it can predict whether cancer has spread to lymph nodes in patients with early-stage papillary thyroid cancer. The goal is to improve treatment planning without unnecessary surgery.
Guangdong, GuangzhouAges Any age - NCT06814496RecruitingPhase 1/Phase 2
Radiation and immunotherapy combo for DLL3-positive cancers
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
Tucson, ArizonaAges 18–99 - NCT06087068RecruitingPhase 2
Thyroid hormone therapy after lobectomy for low-risk thyroid cancer
This trial is testing whether thyroid hormone replacement after surgery is safe for people with low-risk papillary thyroid cancer. It may help maintain normal hormone levels after part of the thyroid is removed.
Beijing, Beijing MunicipalityAges 1.5 years–70 years - NCT06860971RecruitingPhase 3
AL2846 capsule vs placebo for advanced thyroid cancer
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06482086RecruitingPhase 2
Using tumor models to guide drug choice for advanced thyroid cancer
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
Chengdu, SichuanAges 18 years+ - NCT06523582Recruiting
Genetic study of neuroendocrine tumors in Mexican patients
This study aims to find genetic causes of neuroendocrine tumors in Mexican patients. By understanding your DNA, researchers hope to improve diagnosis and treatment for people with these rare conditions.
Mexico City, Mexico CityAges 18 years+
Hear when a new Medullary Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for medullary thyroid carcinoma?
- Yes. Clin2 currently lists 22 recruiting medullary thyroid carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a medullary thyroid carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a medullary thyroid carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.